Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04051606
Title Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

glioblastoma

gliosarcoma

high grade glioma

Therapies

Regorafenib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.